Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Buy
58
VOR Quote, Financials, Valuation and Earnings
Last price:
$2.38
Seasonality move
:
-26.76%
Day range:
$1.92 - $2.37
52-week range:
$0.13 - $3.29
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
4.01x
Volume:
12.5M
Avg. volume:
32.5M
1-year change:
109.9%
Market cap:
$264.9M
Revenue:
--
EPS (TTM):
-$1.51
Analysts' Opinion
-
Consensus RatingVor Biopharma has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 4 Hold ratings, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of $1.18, Vor Biopharma has an estimated downside of -44.58% from its current price of $2.12.
-
Price Target UpsideAccording to analysts, the highest upside price target is $3.00 representing -100% upside increase from its current price of $2.12.
Fair Value
-
According to the consensus of 4 analysts, Vor Biopharma has -44.58% downside to fair value with a price target of $1.18 per share.
VOR vs. S&P 500
-
Over the past 5 trading days, Vor Biopharma has underperformed the S&P 500 by -16.59% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Vor Biopharma does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Vor Biopharma has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Vor Biopharma reported revenues of --.
Earnings Growth
-
Vor Biopharma has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Vor Biopharma reported earnings per share of -$0.26.
Enterprise value:
204.9M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-2.04x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$101M | -$127.9M | -$122.2M | -$32.3M | -$33.3M | |
| EBITDA | -$97.7M | -$124.3M | -$118.7M | -$31.4M | -$32.5M | |
| Diluted EPS | -$2.16 | -$1.77 | -$1.51 | -$0.45 | -$0.26 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $266.3M | $190.3M | $216.9M | $111.8M | $64.8M | |
| Total Assets | $292.9M | $234.3M | $277.5M | $167M | $109.3M | |
| Current Liabilities | $8.6M | $18.1M | $12.6M | $13.2M | $16.7M | |
| Total Liabilities | $25.8M | $39.8M | $47.3M | $44M | $43.2M | |
| Total Equity | $267.2M | $194.4M | $230.2M | $123M | $66.1M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$86.5M | -$106.5M | -$100.3M | -$30.5M | -$31.1M | |
| Cash From Investing | -$80.5M | $108.5M | $52.7M | $44M | -$230K | |
| Cash From Financing | $119.5M | $515K | $52.7M | $96K | -$606K | |
| Free Cash Flow | -$93.1M | -$107.6M | -$100.6M | -$30.6M | -$31.3M | |
VOR
Sector
Market Cap
$264.9M
$34.4M
Price % of 52-Week High
64.44%
48.88%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.01%
1-Year Price Total Return
109.9%
-37.36%
Beta (5-Year)
--
0.614
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$2.40
200-day SMA
Buy
Level
$0.89
Bollinger Bands (100)
Buy
Level
0.16 - 1.38
Chaikin Money Flow
Sell
Level
-62.9M
20-day SMA
Buy
Level
$1.47
Relative Strength Index (RSI14)
Buy
Level
65.22
ADX Line
Sell
Level
17.55
Williams %R
Neutral
Level
-45.384
50-day SMA
Buy
Level
$0.73
MACD (12, 26)
Buy
Level
0.63
25-day Aroon Oscillator
Buy
Level
60
On Balance Volume
Sell
Level
-39.3M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.
Stock Forecast FAQ
In the current month, VOR has received 0 Buy ratings 4 Hold ratings, and 0 Sell ratings. The VOR average analyst price target in the past 3 months is $1.18.
-
Where Will Vor Biopharma Stock Be In 1 Year?
According to analysts, the consensus estimate is that Vor Biopharma share price will drop to $1.18 per share over the next 12 months.
-
What Do Analysts Say About Vor Biopharma?
Analysts are divided on their view about Vor Biopharma share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Vor Biopharma is a Sell and believe this share price will rise from its current level to $0.30.
-
What Is Vor Biopharma's Price Target?
The price target for Vor Biopharma over the next 1-year time period is forecast to be $1.18 according to 4 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 4 analysts rate the stock a Hold.
-
Is VOR A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Vor Biopharma is a Hold. 4 of 4 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of VOR?
You can purchase shares of Vor Biopharma via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Vor Biopharma shares.
-
What Is The Vor Biopharma Share Price Today?
Vor Biopharma was last trading at $2.38 per share. This represents the most recent stock quote for Vor Biopharma. Yesterday, Vor Biopharma closed at $2.12 per share.
-
How To Buy Vor Biopharma Stock Online?
In order to purchase Vor Biopharma stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 4.14% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 7.51% over the past day.
